Spending the cost of Bortezomib ACTe launch for the first injection of patients in need.
Considering the current situation in the country and taking into account the needs of patients, Actero Company decided to spend all the costs related to the unveiling of the drug Bortezomib ACTe on the first free injection of patients’ candidates receiving Bortezomib. »MORE
Breast Cancer Webinar
Simultaneously with the unveiling of Onkotaxel (Docetaxel of Actero Company), a subspecialized webinar was held on July 23rd with the presence of Dr. Safa Najafi (Medical Oncologist), Dr. Samiei (Radiotherapy Oncologist), Dr. Azimi Nejadan (Surgeon) and Ms. Dr. Ehsani (Pathologist) on August 2.»MORE
We are building a unique range of products to cover the needs of cancer patients. Actero is not only focused on chemotherapy, but understands cancer treatment as a whole. That is why we invest in high quality oncology drugs, as well as in palliative care…»MORE